このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vericel 将来の成長

Future 基準チェック /56

Vericelは、50.3%と21.1%でそれぞれ年率50.3%で利益と収益が成長すると予測される一方、EPSはgrowで49.8%年率。

主要情報

49.4%

収益成長率

49.0%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	21.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	20 Jun 2024

今後の成長に関する最新情報

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Recent updates

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Apr 26

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Feb 02

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09

業績と収益の成長予測

NasdaqGM:VCEL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	379	50	N/A	95	5
12/31/2025	300	26	N/A	80	7
12/31/2024	240	5	N/A	50	7
3/31/2024	208	0	2	35	N/A
12/31/2023	198	-3	8	35	N/A
9/30/2023	185	-10	11	32	N/A
6/30/2023	178	-13	13	29	N/A
3/31/2023	169	-17	9	22	N/A
12/31/2022	164	-17	10	18	N/A
9/30/2022	159	-18	14	21	N/A
6/30/2022	155	-16	12	21	N/A
3/31/2022	158	-11	14	22	N/A
12/31/2021	156	-7	21	29	N/A
9/30/2021	154	0	22	30	N/A
6/30/2021	152	9	25	31	N/A
3/31/2021	132	4	19	23	N/A
12/31/2020	124	3	15	18	N/A
9/30/2020	118	0	7	9	N/A
6/30/2020	117	0	10	13	N/A
3/31/2020	123	-12	-6	-3	N/A
12/31/2019	118	-10	-10	-7	N/A
9/30/2019	110	-14	-11	-8	N/A
6/30/2019	102	-18	-17	-14	N/A
3/31/2019	95	-3	-3	-1	N/A
12/31/2018	91	-8	-3	0	N/A
9/30/2018	83	-13	-5	-2	N/A
6/30/2018	75	-17	-12	-9	N/A
3/31/2018	73	-15	-11	-10	N/A
12/31/2017	64	-17	N/A	-13	N/A
9/30/2017	57	-26	N/A	-23	N/A
6/30/2017	54	-29	N/A	-22	N/A
3/31/2017	50	-31	N/A	-22	N/A
12/31/2016	54	-27	N/A	-20	N/A
9/30/2016	53	-26	N/A	-15	N/A
6/30/2016	54	-23	N/A	-11	N/A
3/31/2016	54	-22	N/A	-11	N/A
12/31/2015	51	-23	N/A	-13	N/A
9/30/2015	50	-20	N/A	-16	N/A
6/30/2015	49	-23	N/A	-23	N/A
3/31/2015	40	-25	N/A	-25	N/A
12/31/2014	29	-26	N/A	-25	N/A
9/30/2014	14	-26	N/A	-24	N/A
6/30/2014	4	-21	N/A	-19	N/A
3/31/2014	0	-22	N/A	-18	N/A
12/31/2013	0	-21	N/A	-20	N/A
9/30/2013	0	-25	N/A	-23	N/A
6/30/2013	0	-28	N/A	-26	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VCELの予測収益成長率 (年間50.3% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: VCELの収益 ( 50.3% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: VCELの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: VCELの収益 ( 21.1% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: VCELの収益 ( 21.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VCELの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Vericel 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Vericel Corporation Provides Earnings Guidance for the Year 2024

Price target increased by 11% to US$52.07

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

Price target increased by 7.9% to US$46.23

Vericel Corporation Provides Earnings Guidance for the Year 2024

Recent updates

CEO, President & Director notifies of intention to sell stock

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

New minor risk - Shareholder dilution

Vericel Corporation Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director exercised options to buy US$1.2m worth of stock.

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Vericel Corporation to Report Q1, 2024 Results on May 08, 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation, Annual General Meeting, May 01, 2024

CEO, President & Director notifies of intention to sell stock

Senior VP recently sold US$368k worth of stock

Senior VP notifies of intention to sell stock

Price target increased by 11% to US$52.07

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Full year 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation to Report Q4, 2023 Results on Feb 29, 2024

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Price target increased by 7.9% to US$46.23

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Provides Earnings Guidance for the Year 2024

Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023

Chief Operating Officer exercised options and sold US$492k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Total Net Revenue Guidance for 2023

Vericel Corporation to Report Q3, 2023 Results on Nov 08, 2023

Vericel Corporation Announces U.S. Commercial Availability of NexoBrid (Anacaulase-Bbb) for the Treatment of Severe Thermal Burns in Adults

Consensus estimates of losses per share improve by 15%

Vericel Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vericel Corporation to Report Q2, 2023 Results on Aug 02, 2023

Price target increased by 7.9% to US$40.75

Consensus EPS estimates fall by 12%, revenue upgraded

Vericel Corporation Raises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

Consensus EPS estimates fall by 48%

Chief Operating Officer exercised options and sold US$95k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 7.1% to US$36.67

Vericel Corporation to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$100k worth of stock

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Announces Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Corporation Provides Revenue Guidance for the Full-Year 2022

Vericel Announces Fda Approval of Nexobrid for the Treatment of Severe Thermal Burns in Adults

Price target increased to US$37.00

Price target decreased to US$33.25

Price target decreased to US$38.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Provides Earnings Guidance for the Full-Year 2022

Vericel Corporation to Report Q3, 2022 Results on Nov 09, 2022

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Announces Revenue Guidance for the Full Year of 2022

Vericel Q2 2022 Earnings Preview

Vericel Corporation Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America of Patients with Large Posterior Trunk Burns Treated with Epicel

Vericel Corporation to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$45.20

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Vericel Corporation Reaffirms Earnings Guidance for the Year 2022

Now 21% undervalued after recent price drop

Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Vericel - A Disruptive Business With Years Of Growth Remaining

Chief Medical Officer exercised options and sold US$305k worth of stock

Consensus EPS estimates have been downgraded.